Phaseline

Companies › BeyondBio

BeyondBio: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 3 Phase 1; Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BEY1107–Phase 1Glioblastoma Multiforme; Locally Advanced or Metastatic Pancreatic Cancer; Metastatic Colorectal CancerNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05769660BEY1107Phase 1Glioblastoma MultiformeOncologyNov 2026
NCT03579836BEY1107Phase 1Locally Advanced or Metastatic Pancreatic CancerOncologyNov 2026
NCT05093907BEY1107Phase 1Metastatic Colorectal CancerOncologyNov 2026

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.